First Decade of the National Cancer Institute's Affordable Cancer Technologies Program: Accelerating Translational Technology Research and Development for Cancer Globally.

IF 3 Q2 ONCOLOGY

JCO Global Oncology Pub Date : 2025-07-01 Epub Date: 2025-07-30 DOI:10.1200/GO-25-00200

Paul C Pearlman, Rao Divi, Rebecca Huppi, Elise Garton, Srivatsan Kidambi, Pushpa Tandon, Miguel Ossandon, Ophira Ginsburg, Satish Gopal

{"title":"First Decade of the National Cancer Institute's Affordable Cancer Technologies Program: Accelerating Translational Technology Research and Development for Cancer Globally.","authors":"Paul C Pearlman, Rao Divi, Rebecca Huppi, Elise Garton, Srivatsan Kidambi, Pushpa Tandon, Miguel Ossandon, Ophira Ginsburg, Satish Gopal","doi":"10.1200/GO-25-00200","DOIUrl":null,"url":null,"abstract":"<p><p>Since 2014, the National Cancer Institute Affordable Cancer Technologies (ACTs) program has supported a broad research portfolio focused on the development and validation of new technologies for global cancer control. ACTs projects are conducted by international teams composed of investigators from the United States and low- and middle-income countries, spurring important contextually relevant innovations. During its first decade, the ACTs program ushered in new technology platforms, led to commercialized products, and affected health policies and programs worldwide including in the United States. It has allowed a new generation of investigators working across disciplines and national borders to pursue novel technological solutions and leverage new analytic methods to advance human health. This commentary lays out the scope and accomplishments of the ACTs program to date while considering possible future research directions.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500200"},"PeriodicalIF":3.0000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12320939/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCO Global Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1200/GO-25-00200","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/30 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Since 2014, the National Cancer Institute Affordable Cancer Technologies (ACTs) program has supported a broad research portfolio focused on the development and validation of new technologies for global cancer control. ACTs projects are conducted by international teams composed of investigators from the United States and low- and middle-income countries, spurring important contextually relevant innovations. During its first decade, the ACTs program ushered in new technology platforms, led to commercialized products, and affected health policies and programs worldwide including in the United States. It has allowed a new generation of investigators working across disciplines and national borders to pursue novel technological solutions and leverage new analytic methods to advance human health. This commentary lays out the scope and accomplishments of the ACTs program to date while considering possible future research directions.

Abstract Image

查看原文本刊更多论文

国家癌症研究所负担得起的癌症技术计划的第一个十年：加速全球癌症转化技术研究和开发。

自2014年以来，国家癌症研究所负担得起的癌症技术（ACTs）项目支持了广泛的研究组合，重点是开发和验证全球癌症控制的新技术。以青蒿素为基础的联合治疗项目由来自美国和中低收入国家的调查人员组成的国际小组开展，促进了与具体情况相关的重要创新。在第一个十年中，ACTs项目引入了新的技术平台，导致产品商业化，并影响了包括美国在内的世界各地的卫生政策和项目。它使新一代的研究人员能够跨越学科和国界，寻求新的技术解决方案，并利用新的分析方法来促进人类健康。这篇评论列出了ACTs计划迄今为止的范围和成就，同时考虑了未来可能的研究方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊